No Data
No Data
Maccura Biotechnology Gets Nod to Register Rheumatoid Arthritis Kit
maccura biotechnology (300463.SZ): obtained the product registration certificate for rheumatoid arthritis indicators detection kit
On November 14th, Maccura Biotechnology (300463.SZ) announced that the company recently received the "Medical Instruments Registration Certificate (In Vitro Diagnostic Reagents)" issued by the Sichuan Provincial Drug Administration. The product named Rheumatoid Factor Determination Reagent Kit (Latex Immunoassay Turbidimetry) is used for quantitative measurement of rheumatoid factors in human serum or plasma outside the body.
maccura biotechnology (300463.SZ): cumulatively repurchased 0.65% of shares
On November 1st, Maccura Biotechnology (300463.SZ) announced that, as of October 31, 2024, the company has repurchased a total of 3,958,000 shares through a repurchase dedicated securities account in a centralized competitive trading manner, accounting for 0.65% of the company's current total share capital. The fill price was 12.64 yuan per share, with the highest fill price at 14.48 yuan per share, and the lowest fill price at 10.91 yuan per share. The total amount paid was 50,022,021.82 yuan (excluding transaction fees). This repurchase is in compliance with the company's share repurchase plan and relevant laws and regulations.
Earnings Troubles May Signal Larger Issues for Maccura BiotechnologyLtd (SZSE:300463) Shareholders
Maccura Biotechnology (300463.SZ): It is expected that in the first half of next year, C2000 will be promoted through a production line format.
Gelonghui, October 24th - maccura biotechnology (300463.SZ) stated at the investor relations event that the C2000 and C1000 models have been released, with C1000 just entering the market and Max products not yet widely introduced. It is expected that the C2000 will be promoted through the pipeline form in the first half of next year.
Mike Biotech: Report for the third quarter of 2024
No Data
No Data